0001209191-18-049225.txt : 20180904
0001209191-18-049225.hdr.sgml : 20180904
20180904164849
ACCESSION NUMBER: 0001209191-18-049225
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20180831
FILED AS OF DATE: 20180904
DATE AS OF CHANGE: 20180904
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sebelius Kathleen
CENTRAL INDEX KEY: 0001654316
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37929
FILM NUMBER: 181052857
MAIL ADDRESS:
STREET 1: C/O DERMIRA, INC.
STREET 2: 275 MIDDLEFIELD ROAD, SUITE 150
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Myovant Sciences Ltd.
CENTRAL INDEX KEY: 0001679082
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 20-22 BEDFORD ROW
CITY: LONDON
STATE: X0
ZIP: WC1R 4JS
BUSINESS PHONE: (441) 824-8101
MAIL ADDRESS:
STREET 1: 20-22 BEDFORD ROW
CITY: LONDON
STATE: X0
ZIP: WC1R 4JS
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-08-31
0
0001679082
Myovant Sciences Ltd.
MYOV
0001654316
Sebelius Kathleen
C/O MYOVANT SCIENCES INC.
2000 SIERRA POINT PARKWAY
BRISBANE
CA
94005
1
0
0
0
Stock Option (Right to Buy)
24.25
2018-08-31
4
A
0
22500
0.00
A
2028-08-30
Common Shares
22500
22500
D
100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 31, 2019, and (b) the date that is one day prior to the Issuer's 2019 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date.
/s/Matthew Lang, Attorney-in-fact
2018-09-04
EX-24.4_807849
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
(For Executing Form ID and Forms 3, 4 and 5)
Know all by these presents, that the undersigned hereby constitutes and
appoints each of the persons set forth on Exhibit A, signing individually, the
undersigned's true and lawful attorney-in fact and agent to:
(1) Prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the the Securities and Exchange Commission (the "SEC") Form ID and
Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in
connection therewith) in accordance with Section 16(a) of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder
in the undersigned's capacity as an officer, director or beneficial owner of
more than 10% of a registered class of securities of Myovant Sciences Ltd. (the
"Company");
(2) Do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to prepare and execute any such Form ID and Forms
3, 4 or 5 (including amendments thereto and joint filing agreements in
connection therewith) and file such forms with the SEC and any stock exchange,
self-regulatory association or any similar authority; and
(3) Take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required of the undersigned, it being
understood that the documents executed by the attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as the attorney-in-fact may approve in the
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted. The
undersigned acknowledges that the foregoing attorneys-in-fact, and their
substitutes, in serving in such capacity at the request of the undersigned, are
not assuming (nor is the Company assuming) any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the Company and the foregoing attorneys-in fact or (c) as to any
attorney-in-fact individually, until such attorney-in-fact is no longer employed
by the Company, or any of its subsidiaries, or Cooley LLP, as applicable.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.
Date: June 6, 2018
By: /s/ Kathleen Sebelius
Kathleen Sebelius
Exhibit A
Authorized Persons
Frank Karbe, Myovant Sciences, Inc.
Matthew Lang, Myovant Sciences, Inc.
Yang (Christine) Liu, Myovant Sciences, Inc.
Kenneth Guernsey, Cooley LLP
Alison Haggerty, Cooley LLP